

Disclosures

Personal Commercial (31)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|--------------------|
| Self | | | |
| Allelica | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Allelica | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Amgen Inc. | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Apple | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Apple | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| AstraZeneca Pharmaceuticals | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Blackstone Life Sciences | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Bolt | Stock | Modest (< \$5,000) | Other |
| Boston Scientific | Research/Research Grants ‡ NCT03416920 | Significant (>= \$5,000) | Prevention |
| Candela | Stock | Modest (< \$5,000) | Other |
| CRISPR Therapeutics | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Eli Lilly and Company | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Esperion Therapeutics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| Foresite Capital | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Foresite Labs | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Genentech, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| GV (formerly Google Ventures) | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| HeartFlow | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Magnet Biomedicine | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Merck & Co., Inc. | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Mercury | Stock | Modest (< \$5,000) | Other |
| MyOme | Stock | Modest (< \$5,000) | Other |
| Novartis Corporation | Research/Research Grants | Significant (>= \$5,000) | Prevention |
| Novartis Corporation | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Parameter Health | Stock | Modest (< \$5,000) | Prevention |
| Preciseli | Stock | Modest (< \$5,000) | General Cardiology |
| TenSixteen Bio | Stock | Significant (>= \$5,000) | General Cardiology |
| TenSixteen Bio | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| Spouse/Domestic Partner/Immediate Household Member | | | |
| Vertex Pharmaceuticals | Stock | Significant (>= \$5,000) | Other |
| Vertex Pharmaceuticals | Salary | Significant (>= \$5,000) | Other |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|--------------------------|--------------------------|-------------------|
| Self | | | |
| Fondation Leducq † <i>Fondation Leducq</i> | Research/Research Grants | Significant (>= \$5,000) | <i>Prevention</i> |
| National Institutes of Health | Research/Research Grants | Significant (>= \$5,000) | <i>Prevention</i> |

Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|------------|---------------|----------------------|
| EVOLVE-MI | Amgen | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† *Commercial Funding Source* | ‡ *Trial Name*

Agreement

Certified Education Attestation | Signed on 8/26/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/26/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 8/26/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 8/26/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.